Abstract
BackgroundThis study evaluated the safety and efficacy of repeat SBRT for local recurrence of stage I non-small-cell lung cancer (NSCLC) and solitary lung metastasis.MethodsThirty-one patients with in-field local relapse of NSCLC (n = 23) or lung metastasis (n = 8) underwent repeat SBRT. All patients had grade 2 or lower radiation pneumonitis after the first SBRT. Local recurrence was diagnosed with CT and FDG-PET in 17 patients and by biopsy in 14. The median interval between the first and second SBRT was 18 months (range, 4–80). The first SBRT dose was mainly 48–52 Gy in 4 fractions (n = 25) according to the institutional protocols. Second SBRT doses were determined based on the tumor size and distance to organs at risk, and were mostly 48–52 Gy in 4 fractions (n = 13) or 60 Gy in 8 fractions (n = 13).ResultsAt 3 years, overall survival and local control rates were 36 and 53%, respectively, for all 31 patients. Four patients showed no further recurrence for > 5 years (63–111 months) after the second SBRT. Radiation pneumonitis after the second SBRT was grade 2 in 4 patients, and no grade 3 pneumonitis was observed.ConclusionRepeat SBRT was safe. Local control and survival rates were higher than expected. SBRT should be an important treatment option for local recurrence of NSCLC or lung metastasis after previous local SBRT.Trial registrationThis retrospective study was approved by the ethics committee of our institution (September, 2017; approval number: 27–10).
Highlights
This study evaluated the safety and efficacy of repeat Stereotactic body radiotherapy (SBRT) for local recurrence of stage I non-smallcell lung cancer (NSCLC) and solitary lung metastasis
Previous studies suggested that late radiation damage that was previously considered unrecoverable may recover to some extent [11], and this may especially be the case for the lung [12]
Our series is the largest one with the longest follow-up periods among studies of second SBRT for lung tumors. Study design This was a retrospective analysis of second-line treatment with repeat SBRT for patients who had undergone SBRT for stage I NSCLC and solitary lung metastasis
Summary
This study evaluated the safety and efficacy of repeat SBRT for local recurrence of stage I non-smallcell lung cancer (NSCLC) and solitary lung metastasis. Stereotactic body radiotherapy (SBRT) has been established as one of the standard treatments for stage I non-small-cell lung cancer (NSCLC) and solitary lung metastasis. Ogawa et al Radiation Oncology (2018) 13:136 recent investigations have revealed that re-irradiation could be relatively safely applied to tumors at various sites, especially when the treatment volume could be limited to a small one [8,9,10]. Previous studies suggested that late radiation damage that was previously considered unrecoverable may recover to some extent [11], and this may especially be the case for the lung [12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
